Neurolentech is a pioneering brand in the field of precision medicine for neurodevelopmental disorders. With more than 2% of the population affected by conditions such as epilepsy, severe autism, and intellectual disability, the impact on patients, families, and society is significant. However, there are currently no cures or effective medications available.

That's where Neurolentech comes in. Founded in 2020 as a spin-out from IST Austria, Neurolentech utilizes cutting-edge scientific laboratory techniques to develop patient-derived neuronal cell models. By reprogramming stem cells generated from each patient's blood or skin cells into genetically and functionally identical brain cells, they gain valuable insights into the molecular mechanisms of each neurodevelopmental disorder.

This deep understanding allows Neurolentech to identify potentially druggable targets and develop new therapeutic approaches in collaboration with biopharma companies. The data gathered from individual patients and their corresponding cell models also enables the development of suitable diagnostic tools. With its commitment to precision medicine, Neurolentech is dedicated to making a tangible difference in the lives of those affected by neurodevelopmental disorders